Pharmacogenetics, Pharmacogenomics, and Individualized Medicine

10.1097/01.fpc.0000189800.88596.7a

10.1016/j.jacc.2006.11.044

10.1161/CIRCULATIONAHA.108.832139

10.1080/03602530801952187

Bell, 1978, Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K–epoxide cycle, Fed Proc, 37, 2599

10.1111/j.1538-7836.2005.01449.x

10.1016/j.clpt.2006.03.013

10.1592/phco.28.2.141

10.1001/jama.291.23.2821

10.1038/clpt.2010.94

10.1038/428486a

Dahl, 1995, Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis, J Pharmacol Exp Ther, 274, 516

10.1038/ng.379

Davidson, 1997, The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day, Am J Cardiol, 79, 38, 10.1016/S0002-9149(96)00742-4

10.1038/sj.clpt.6100019

10.1056/NEJMoa010819

10.1182/blood-2008-07-077958

10.1146/annurev.med.56.082103.104724

10.1136/bmj.2.5197.485

10.1056/NEJMra020526

10.1126/science.286.5439.487

10.1038/nature02626

Farlow, 1998, Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease, Neurology, 50, 669, 10.1212/WNL.50.3.669

10.1016/S0009-9236(99)70075-5

10.1007/s11239-007-0104-y

10.1200/JCO.2005.03.3266

10.1080/03602530801952617

10.1054/bjoc.2000.1265

10.1124/dmd.109.028498

10.1016/S0009-9236(03)00168-1

10.1097/01.fpc.0000199500.46842.4a

10.1056/NEJMoa0809329

10.1111/j.1523-1755.1998.00847.x

10.1093/jnci/dji005

10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z

Kalow, 1959, Some statistical data on atypical cholinesterase of human serum, Ann Hum Genet, 23, 239, 10.1111/j.1469-1809.1959.tb01467.x

10.1139/o57-148

10.1097/00008571-199808000-00001

10.1038/clpt.2009.79

10.1177/0091270008328098

10.1016/S0002-9343(99)00067-4

10.1038/86882

10.1097/00008571-200203000-00006

10.1097/00008571-200204000-00010

10.1038/nature02254

10.1016/S0009-9236(99)70071-8

10.1592/phco.28.9.1084

10.2174/138920007779816002

10.1146/annurev.pharmtox.41.1.535

Liu, 2010, Angiotensin-converting enzyme gene I/D genotype affected metoprolol-induced reduction in 24-hour average heart rate, Chin Med J (Engl), 123, 1382

Lu, 1998, Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety, Drug Metab Dispos, 26, 1217

Lu AYH Ma Q (2010) Pharmacogenetics and individualized medicine, in ADME-Enabling Technologies in Drug Design and Development ( Zhang D Surapaneni S eds), in press. Wiley & Sons, New York.

10.1056/NEJMoa040938

10.1021/tx0200919

10.2174/138920008784746337

10.1111/j.1600-6143.2004.00435.x

10.1016/S0140-6736(02)07873-X

10.1056/NEJMoa0706135

10.1073/pnas.0307067101

10.1056/NEJM199806183382502

10.1161/01.CIR.0000130846.46168.03

10.1146/annurev.pharmtox.41.1.101

10.1161/CIRCULATIONAHA.109.851949

10.1016/S0140-6736(00)03167-6

10.1124/dmd.108.021816

10.1016/j.clpt.2003.12.016

10.1016/j.tips.2006.09.008

10.1080/03602530801952864

10.1016/j.clpt.2005.01.018

10.1016/S0009-9236(03)00060-2

10.7326/0003-4819-137-12-200212170-00007

10.1097/01.fpc.0000230416.82349.90

Pirmohamed, 2001, TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients, Neurology, 56, 890, 10.1212/WNL.56.7.890

10.1073/pnas.92.26.12260

10.1124/dmd.108.023143

10.1124/mi.6.4.8

10.1056/NEJMoa044503

10.1124/mi.10.1.4

10.7326/0003-4819-145-10-200611210-00007

10.1038/nature02214

10.1038/35057149

10.1023/A:1012244520615

10.1038/382722a0

10.1067/mcp.2000.104391

10.1016/j.clpt.2004.05.002

10.1016/j.clpt.2006.04.008

10.1056/NEJMoa0801936

10.1073/pnas.180223197

10.1038/ng.632

10.1126/science.277.5328.959

10.1016/j.clpt.2004.03.003

10.1038/clpt.2009.297

Stern, 1985, Notification and risk assessment for bladder cancer of a cohort exposed to aromatic amines. III. Mortality among workers exposed to aromatic amines in the last beta-naphthylamine manufacturing facility in the United States, J Occup Med, 27, 495

10.1093/hmg/ddh149

Thervet, 2010, Optimization of initial tacrolimus dose using pharmacogenetic testing, Clin Pharmacol Ther, 87, 721

10.1074/jbc.M103792200

10.1038/clpt.2009.232

10.1146/annurev.pharmtox.40.1.581

10.1124/mol.62.3.446

Verstuyft, 2003, Digoxin pharmacokinetics and MDR1 genetic polymorphisms, Eur J Clin Pharmacol, 58, 809, 10.1007/s00228-003-0567-5

10.1016/0163-7258(89)90130-7

10.1038/clpt.2009.291

10.1038/sj.tpj.6500313

10.1007/s00439-006-0260-8

10.1124/dmd.109.029694

Weber WW (1987) The Acetylator Genes and Drug Response, Oxford University Press, New York.

10.1056/NEJMra020021

10.1124/mi.3.3.118

10.1124/dmd.104.000794

10.1038/clpt.2009.240

10.1161/CIRCULATIONAHA.107.740324

10.1124/dmd.107.017806

10.1124/dmd.108.025981

10.1016/j.cca.2006.05.010

10.2174/138920008786049302